0001299130-22-000006.txt : 20220111 0001299130-22-000006.hdr.sgml : 20220111 20220111070301 ACCESSION NUMBER: 0001299130-22-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220111 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20220111 DATE AS OF CHANGE: 20220111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 22522729 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20220111x8k.htm 8-K pacb-20220111x8k
false000129913000012991302022-01-112022-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 11, 2022

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-34899

16-1590339

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PACB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.    Results of Operations and Financial Condition.

On January 11, 2022, Pacific Biosciences of California, Inc. issued a press release announcing certain unaudited preliminary financial results for the fourth quarter ended December 31, 2021. A copy of the press release is furnished hereto as Exhibit 99.1.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS.

5

(d)

Exhibits.

Exhibit No.

Description

99.1

Press Release issued by Pacific Biosciences of California, Inc., dated January 11, 2022

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)


‎

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Date: January 11, 2022

By:

/s/ Michele Farmer

Michele Farmer

Vice President and Chief Accounting Officer

 EX-99.1 2 pacb-20220111xex99_1.htm EX-99.1 Exhibit 991 press release

Exhibit 99.1



PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations

MENLO PARK, Calif. – January 11, 2022 – PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available.

Business Updates:

·

Expect preliminary fourth quarter revenue of approximately $36.0 million, representing an increase of approximately 33% compared with $27.1 million for the fourth quarter of 2020. As a result, preliminary annual 2021 revenue is expected to be $130.5 million, representing a growth of approximately 65% from 2020.

·

Placed a record of 48 Sequel II/IIe systems during the fourth quarter compared to 35 Sequel II/IIe systems placed in the prior year quarter. Sequel II/IIe installed base was, therefore, 374 units as of December 31, 2021, compared with 203 as of December 31, 2020.

·

Announced plans to launch new library prep and sequencing kits for the Sequel II/IIe platform in the first half of 2022. The new kits will lower DNA input requirements by 40% which will enable customers to access more samples than ever before. Additionally, the new kits will simplify users’ workflow with >60% reduction in hands-on time and >30% fewer tubes.

·

Developed significant improvements to the Sequel II/IIe platform that will be released in first half of 2022, including on-instrument methylation calling, standardized gene editing QC workflows, and high throughput setup capabilities, including automation scripts for liquid handling.

·

Finalized expansion of collaboration with Invitae Corporation to include PacBio's proprietary, Sequencing by Binding, short-read sequencing platform. The collaboration will initially focus on precision oncology with an emphasis on liquid biopsy and minimal residual disease (MRD).

·

Collaborated with Twist Bioscience to deliver optimized, HiFi-enabled target capture workflows and help our customers obtain high-quality phased data for clinically important targets at lower per sample costs.



Preliminary instrument revenue for the fourth quarter of 2021 is expected to be approximately $16.2 million, compared with $15.9 million for the third quarter of 2021, and compared with $13.6 million for the fourth quarter of 2020. Preliminary consumables revenue for the fourth quarter of 2021 is expected to be approximately $15.0 million, compared with $14.6 million for the third quarter of 2021, and compared with $10.0 million for the fourth quarter of 2020. Preliminary service and other revenue for the fourth quarter of 2021 is expected to be approximately $4.8 million, compared with $4.4 million for the third quarter of 2021, and compared with $3.5 million for the fourth quarter of 2020.



"2021 was a transformational year for PacBio. We dramatically expanded our leadership team, achieved record revenues and Sequel II/IIe installations, and completed the first two acquisitions in company history, enabling us to become the only company with leading long and short-read sequencing technologies. Importantly, we are also collaborating with more customers than ever before to help us demonstrate the power of HiFi sequencing in numerous applications,” said Christian Henry, CEO and President of PacBio. “The fourth quarter represented sustained execution on our goals as we achieved record revenue, record Sequel II/IIe placements, and launched our COVID surveillance solution, HiFi Viral, which is PacBio’s first kitted sequencing solution. In addition, we made significant progress in developing our highly accurate short-read sequencing platform by implementing a new clustering method to facilitate a more robust workflow. As a result of this early success, we remain on track to launch our new short-read, Sequencing by Binding (SBB) technology, in 2023. I expect 2022 to be an exciting year for the company as we leverage the foundation that we’ve built in 2021 and enter the late stages of development for multiple new sequencing platforms.”

 



The Company's actual results for the three months ended December 31, 2021 have not been audited and may differ materially from the preliminary estimates above, which are not a comprehensive statement of the Company's financial results and are not necessarily indicative of the results to be expected for fiscal 2021 or any future period.



The Company is scheduled to present at the 2022 JP Morgan Healthcare Conference on January 13, 2022 at 9:00 am Pacific Time. The Company expects to report its fourth quarter 2021 results during a conference call in mid-February, at which point the Company will discuss its 2021 financial results in more detail.



About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate  sequencing platforms. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.



Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including, among other things, statements relating to our preliminary financial results for the fourth quarter ended December 31, 2021, including our revenue and our installed instruments during the quarter; future products, technologies, workflows and software updates, including in connection with the availability and release dates, uses, accuracy, advantages, quality, performance, and benefits or expected benefits of using PacBio such products, technologies, workflows and software updates; the suitability or utility of such new products, technologies workflows and software updates for particular applications or projects; product development initiatives; and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Investors:

Todd Friedman

650.521.8450

ir@pacificbiosciences.com 



Media:
Kathy Lynch
pr@pacificbiosciences.com 

 



EX-101.SCH 3 pacb-20220111.xsd EX-101.SCH 00090 - Document - Document And Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 4 pacb-20220111_lab.xml EX-101.LAB EX-101.PRE 5 pacb-20220111_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document And Entity Information
Jan. 11, 2022
Document And Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jan. 11, 2022
Entity Registrant Name Pacific Biosciences of California, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-34899
Entity Tax Identification Number 16-1590339
Entity Address, Address Line One 1305 O’Brien Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 650
Local Phone Number 521-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PACB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001299130
XML 7 pacb-20220111x8k_htm.xml IDEA: XBRL DOCUMENT 0001299130 2022-01-11 2022-01-11 false 0001299130 8-K 2022-01-11 Pacific Biosciences of California, Inc. DE 001-34899 16-1590339 1305 O’Brien Drive Menlo Park CA 94025 650 521-8000 false false false false Common Stock, par value $0.001 per share PACB NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.pacb.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports pacb-20220111x8k.htm pacb-20220111.xsd pacb-20220111_lab.xml pacb-20220111_pre.xml pacb-20220111xex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pacb-20220111x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "pacb-20220111x8k.htm" ] }, "labelLink": { "local": [ "pacb-20220111_lab.xml" ] }, "presentationLink": { "local": [ "pacb-20220111_pre.xml" ] }, "schema": { "local": [ "pacb-20220111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pacb", "nsuri": "http://www.pacb.com/20220111", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "pacb-20220111x8k.htm", "contextRef": "Duration_1_11_2022_To_1_11_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document And Entity Information", "role": "http://www.pacb.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "pacb-20220111x8k.htm", "contextRef": "Duration_1_11_2022_To_1_11_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.pacb.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001299130-22-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001299130-22-000006-xbrl.zip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end